Prevention of perinatal HIV infection

Public health approach to emerging infections among pregnant women

As public health professionals respond to emerging infections, particular attention needs to be paid to pregnant women and their offspring. Pregnant women might be more susceptible to, or more severely affected by, emerging infections. The effects of a new maternal infection on the embryo or fetus are difficult to predict. Some medications recommended for prophylaxis or treatment could harm the embryo or fetus. We discuss the challenges of responding to emerging infections among pregnant women, and we propose strategies for overcoming these challenges.

Infecção pelo HIV durante a gestação: estudo-Sentinela Parturiente, Brasil, 2002

OBJETIVO: Avaliar a cobertura efetiva da detecção da infecção pelo HIV durante a gestação, em âmbito nacional. MÉTODOS: A cobertura efetiva do teste de HIV na gestação foi definida como a proporção de gestantes que teve atendimento pré-natal (pelo menos uma consulta), pedido de teste de HIV e conhecimento do resultado antes do parto, sendo estimada por processo de amostragem, utilizando-se as informações coletadas no Estudo-Sentinela Parturiente, 2002. As desigualdades da cobertura efetiva foram analisadas por: grande região; tamanho populacional do município de ocorrência do parto; e grau de instrução da mãe. RESULTADOS: A cobertura efetiva do teste de HIV durante a gestação foi estimada em 52%. As enormes desigualdades socioespaciais ficaram evidenciadas na comparação entre as regiões Nordeste (24%) e Sul (72%); entre parturientes analfabetas (19%) com as que têm o ensino fundamental completo (64%); entre as que realizaram o parto em municípios pequenos (36%) com as que o realizaram em municípios com mais de 500 mil habitantes (66%). As recomendações do Ministério da Saúde foram atendidas, completamente, por somente 27% parturientes. CONCLUSÕES: Os resultados estabelecem a necessidade de haver medidas voltadas para maior cobertura da detecção do HIV na gestação, e indicam que os programas do Programa Nacional de DST e Aids e os programas de saúde da mulher devem ser intensificados, com estratégias conjuntas entre eles.

Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999

BACKGROUND

With implementation of highly active antiretroviral therapy during 1995 through 1999, deaths reported in adults with HIV infection decreased 67%, and the proportions of those accompanied by various opportunistic infections decreased, whereas their proportions with possibly unrelated conditions (e.g. diseases of liver, kidneys and heart) increased.

OBJECTIVE

To examine changes among deaths of children with HIV infection.

METHODS

We analyzed multiple-cause death certificate data with any mention of HIV infection for all US deaths at ages <13 years from 1987 through 1999. We examined changes in the numbers and rates of deaths and the proportions reported with various diseases.

RESULTS

The annual number of children who died with HIV infection increased from 274 in 1987 to 511 in 1994 and then decreased by 81% to 97 in 1999. The median age at death increased from 1 year in 1987 to 5 years in 1999. During the periods 1987 through 1991 (1652 deaths), 1992 through 1995 (1906 deaths) and 1996 through 1999 (762 deaths), the proportion of deaths with pneumocystosis decreased from 19.0% to 9.9% and 7.5%, respectively. In a comparison of 1992 through 1995 with 1996 through 1999, no significant change occurred in the proportions of deaths with nontuberculous mycobacteriosis (5.6% to 6.0%), cytomegalovirus disease (3.2% to 4.4%), heart disease (10.8% to 11.7%), kidney disease (5.0%), liver disease (3.9% to 4.1%) or wasting/cachexia (4.0% to 5.0%).

CONCLUSIONS

Deaths with HIV infection among children have decreased substantially, probably because of both highly active antiretroviral therapy and prevention of perinatal HIV transmission. The decrease after 1995 was greater proportionally among children than among adults, but fewer changes in disease proportions occurred among children.

Antiretroviral therapy in HIV-infected pregnant women and their infants: current interventions and challenges

Advances in antiretroviral therapy for human immunodeficiency virus (HIV)-infected pregnant women have improved maternal health and successfully reduced perinatal transmission from 25% to less than 5%. Maternal treatment is individualized and based on physical and laboratory evaluations. Three categories of drugs are currently approved for use in HIV disease including: (11 nucleoside and nucleotide reverse transcriptase inhibitors; (2) non-nucleoside reverse transcriptase inhibitors; and (3) protease inhibitors. Treatment decisions during pregnancy are complex and require consideration of the physiologic changes of pregnancy, drug interactions, possible maternal and fetal side effects, and psychosocial issues that influence adherence to the chosen therapy.